Association of Salivary Proline-Rich Proteins With Progression of Atherosclerosis in Patients With Cardiovascular Diseases

Association of Salivary Proline-Rich Proteins With Progression of Atherosclerosis in Patients With Cardiovascular Diseases - Association of Salivary Proline-Rich Proteins With Progression of Atherosclerosis in Patients With Cardiovascular Diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048098

Enrollment

1000

Registered

2022-06-20

Start date

2022-05-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with cardiovascular diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are hospitalized for cardiovascular diseases

Exclusion criteria

Exclusion criteria: 1. Patients who cannot provide saliva 2. Patients who do not provide informed consent 3. Patients undergoing hemodialysis 4. Patients who are considered inappropriate for the study by the research medical doctor

Design outcomes

Primary

Measure	Time frame
Association between salivary hPRB1 level and clinical data at admission.	—

Secondary

Measure	Time frame
Clinical outcomes (major adverse cardiovascular events, death, cardiovascular death, non-cardiovascular death, myocardial infarction, stent thrombosis, revascularization, cerebrovascular event, heart failure admission, bleeding, acute renal failure, amputation) Relationship between and salivary hPRB1 concentrations and aortic calcification. Relationship between salivary hPRB1 concentrations and MAC. Relationship between salivary hPRB1 concentrations and coronary artery calcification. Relationship between salivary hPRB1 concentrations and arterial stiffness. Overall and sub-group analyses stratified by HFpEF, AF, TAVI, PCI, EVT, and ablation for AF.	—

Measure

Time frame

Clinical outcomes (major adverse cardiovascular events, death, cardiovascular death, non-cardiovascular death, myocardial infarction, stent thrombosis, revascularization, cerebrovascular event, heart failure admission, bleeding, acute renal failure, amputation) Relationship between and salivary hPRB1 concentrations and aortic calcification. Relationship between salivary hPRB1 concentrations and MAC. Relationship between salivary hPRB1 concentrations and coronary artery calcification. Relationship between salivary hPRB1 concentrations and arterial stiffness. Overall and sub-group analyses stratified by HFpEF, AF, TAVI, PCI, EVT, and ablation for AF.

—

Countries

Japan

Contacts

Public ContactYusuke kanzaki

Shinshu University School of Medicine Department of Cardiovascular Medicine

kanzaki@shinshu-u.ac.jp0263-37-3486

Outcome results